Open an account

Lexaria Bioscience

LEXX · NASDAQ

$3.08+$0.09 (+3.01%)TodayMarket closed ·
Prev close $2.99

About LEXX

Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. The company is headquartered in Kelowna, British Columbia and currently employs 7 full-time employees. The company went IPO on 2009-10-28. The firm's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. The company is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The firm operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.

Employees
7
Headquarters
Kelowna, British Columbia
Listed
Oct 28, 2009
Sector
Health Care
Industry
Pharmaceuticals
Website
lexariabioscience.com

LEXX key statistics

Market cap
6.49M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
65.55K
Volume
23.25K
Open price
$2.98
High today
$3.20
Low today
$2.84
52 Week high
$21.60
52 Week low
$2.43

Lexaria Bioscience (LEXX) at a glance

Lexaria Bioscience (LEXX) last traded at $3.08, with a market cap of 6.49M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.84 and $3.20. The current price is 8.5% above the day's low and 3.7% below its high.

Volume so far is 23.25K shares, below the average of 65.55K shares a day.

Over the past year Lexaria Bioscience has ranged from $2.43 to $21.60, and now sits 3% of the way up that range.

Lexaria Bioscience met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q3 FY26 it reported -$1.20 per share against an estimate of -$1.30.

The average analyst price target is $53.55, 1638.6% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $53.55
Low
$22.73
Now
$3.08
High
$86.63

LEXX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 23.4% on average.

  1. Q4 FY24: reported -$2.10 per share against an estimate of -$1.68
  2. Q1 FY25: reported -$2.40 per share against an estimate of -$1.84
  3. Q2 FY25: reported -$2.25 per share against an estimate of -$2.37
  4. Q3 FY25: reported -$3.15 per share against an estimate of -$2.40
  5. Q4 FY25: reported -$1.95 per share against an estimate of -$2.40
  6. Q1 FY26: reported -$1.05 per share against an estimate of -$1.99
  7. Q2 FY26: reported -$0.90 per share against an estimate of -$1.45
  8. Q3 FY26: reported -$1.20 per share against an estimate of -$1.30

LEXX news

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Avi Kapoor

    Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings

  • Avi Kapoor

    Dow Tumbles 450 Points; US Small Business Sentiment Declines In August

  • Henry Khederian

    Lexaria Bioscience Stock Rallies Thursday: What Investors Need to Know

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Press releaseGlobe Newswire

    THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point

  • Press releaseACCESS Newswire

    Lexaria Releases Annual Letter from the CEO

  • Vandana Singh

    Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus

Similar companies

Companies in the same industry as Lexaria Bioscience

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.